StatinTB is funded by the second European and Developing Countries Clinical Trials Partnership (EDCTP2) and will receive € 5 million over the duration of five and a half years starting in January 2019.
The international consortium will implement a proof-of-concept clinical trial to evaluate whether statins, widely used cholesterol-lowering drugs, could be employed as a repurposed drug for host-directed drug therapy (HDT) in tuberculosis.
In addition to the clinical trial, capacity building for the University of Namibia is an important pillar of the project, with activities planned to train clinical, laboratory and administrative staff.